Abstract 1527
Background
Cancer patients in good general condition can receive aggressive anti-cancer treatment, while palliative care is most appropriate for advanced cancer patients. In China, patients admit to 3A hospitals regardless of the disease stage. Given the limited number of 3A hospital beds, high price, low quality of life, family sickbed is emerging. With one-to-one help of The Second Affiliated Hospital of FMU, Dongshi Township Health Center (DTHC) established the first family sickbed project for oncology patients (FSOP) in China.
Methods
A retrospective survey was adopted to analyze the general clinical data of patients, hospitalization days and expenses, the types of medical insurance and the opioid analgesics drugs used of 225 patients. And, we carried out telephone follow-up to collect the data concerning the patient’s survival and satisfaction with FSOP service.
Results
From 2015 to 2017, 225 patients were admitted to FSOP. Of 225 patients, 192 (85.3%) were males and 33 (14.7%) were females with ages from 24 to 91 years. The most common disease categories were lung cancer, esophagus cancer, liver cancer. 216 out of 225 patients purchased the NCMS Insurance. During those 3 years, the average total hospitalization expenses, the average personal expenses, the average personal expenses ratio, the average reimbursement ratio, and the average hospitalization days of all patients were 3824.24yuan, 1195.34yuan, 34.64%, 65.37% and 11.79 days, respectively. 51 out of 225 patients suffered pain and needed to eat painkillers. The use of Morphine tablets and OxyContin increased year by year, conforming to the principle of the WHO’s three-step analgesic ladder. Follow-up results showed that 37 (18.5%, 37/200) patients were survive, and 177 patients or family members (88.5%, 177/200) were fully satisfied with FSOP’s service.
Conclusions
Since 2015, the DTHC has provided considerate home care, resulting in a high level of patient and family members satisfaction. Admitting to FSOP can lower the hospitalization expenses, decrease the burden of economy and life, improve the quality of life, and relieve the pain, both mental and physical. Moreover, FSOP will be a more appropriate place to spend the last days for advanced cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Second Affiliated Hospital of Fujian Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract